spacer
home > ict > autumn 2016 > get involved
PUBLICATIONS
International Clinical Trials

Get Involved

Several studies have shown that applications of mHealth in healthcare settings have improved medication and procedural compliance (1); however, little research has been conducted on the effect of mHealth on clinical trial adherence and patient retention.

Clinical Ink piloted an mHealth sub-study with 30 subjects using a hybrid bring-your-own-device (BYOD)/provisioned device model, and results have indicated a low 6% subject dropout rate; a high average study procedure compliance of 84%; and high data quality. These data suggest that mHealth has an impact on reducing subject dropout rates, potentially improving protocol adherence and changing patient behaviour.

Research has shown that mHealth significantly enhances medication adherence, reduces non-adherence related adverse effects, and is accepted in healthcare in various geographic settings and among diverse demographic groups (1). Studies have also demonstrated that mHealth improves both recruitment and enrolment in clinical trials (2,3). Considering this with data showing nearly 43% of the global population and 68% of US adults owning a smartphone in 2015, advancing a BYOD approach (such as apps on a patient’s smartphone) in mHealth is inevitable (4,5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kyle Hogan is eClinical Solutions Director with Clinical Ink, and is responsible for the strategic alignment of the company’s native mobile application for clinical trials. Kyle has delivered technical solutions for complex business challenges since the 1990s, and has more than nine years of experience in clinical trials.
spacer
Kyle Hogan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Teknova completes FDA notification for room temperature-stable viral transport medium

Hollister, CA – 16 Dec 2020. Teknova, a leading manufacturer of cell culture media and supplements, purification buffers, and molecular biology reagents, has completed the process of FDA notification for its Active Viral Transport Medium (ATM). ATM is a room temperature-stable version of Teknova’s CDC formulation Viral Transport Medium (VTM) and is manufactured under GMP conditions in compliance with ISO 13485 standards.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement